Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEWGAM in Primary Immune Thrombocytopenia
2009-014589-24Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Apr 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of subcuvia in immune thrombocytopenia (ITP), sponsored by Octapharma. Primary endpoint: Platelet response by Day 8. Started Apr 2011; status: terminated.
02
Drugs
subcuvia
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2009-014589-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014589-24.